# Evaluation of The Performance of Retinow AI Software

> **NCT06645964** · — · COMPLETED · sponsor: **Retinow Health Technologies and R&D Industry Joint Stock Company** · enrollment: 915 (actual)

## Conditions studied

- Diabetic Retinopathy
- Glaucoma
- Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06645964
- **Lead sponsor:** Retinow Health Technologies and R&D Industry Joint Stock Company
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 915 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06645964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06645964, "Evaluation of The Performance of Retinow AI Software". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06645964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*